Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration.

about

Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration.

Item

http://www.wikidata.org/entity/Q55380684

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Ilixadencel - an Allogeneic Ce ...... r Intratumoral Administration.

@en

Ilixadencel - an Allogeneic Ce ...... r Intratumoral Administration.

@nl

type

Item

label

Ilixadencel - an Allogeneic Ce ...... r Intratumoral Administration.

@en

Ilixadencel - an Allogeneic Ce ...... r Intratumoral Administration.

@nl

prefLabel

Ilixadencel - an Allogeneic Ce ...... r Intratumoral Administration.

@en

Ilixadencel - an Allogeneic Ce ...... r Intratumoral Administration.

@nl

P1476

Ilixadencel - an Allogeneic Ce ...... r Intratumoral Administration.

@en

P2093

Alex Karlsson-Parra

http://www.w3.org/2001/XMLSchema#string

Emilia Heimann

http://www.w3.org/2001/XMLSchema#string

Juliana Kovacka

http://www.w3.org/2001/XMLSchema#string

Margareth Jorvid

http://www.w3.org/2001/XMLSchema#string

Peter Suenaert

http://www.w3.org/2001/XMLSchema#string

Sharon Longhurst

http://www.w3.org/2001/XMLSchema#string

Sijme Zeilemaker

http://www.w3.org/2001/XMLSchema#string

P2860

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.

The makings of a tumor rejection antigen.

Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.

Influenza A virus infection of human primary dendritic cells impairs their ability to cross-present antigen to CD8 T cells.

Neoantigens in cancer immunotherapy.

P304

156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-018-2438-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29904904

http://www.w3.org/2001/XMLSchema#string

P932

6002422

http://www.w3.org/2001/XMLSchema#string